Medical cannabis companies should pay for research into women’s pain rather than simply talking about it, two experts have told a conference in Germany. The call was reported by CannabisHealth, which covered the event.

Dr Shabnam Sarshar, founder of the women’s health education platform The Recalibration, and Professor Sylvia Mechsner, who leads the endometriosis centre at Berlin’s Charité university hospital, spoke at the Cannabis Health Symposium in Frankfurt on 4 November. Their session was titled Endometriosis and Beyond: Medical Cannabis in Women’s Health.

Sarshar challenged firms to move beyond what she called “woman-washing” and commit budgets to research. “We should do better,” she told attendees.

Call for €300,000 for basic research

Mechsner appealed for €300,000 to study how cannabinoids interact with the tissue and nerves affected by endometriosis, a chronic inflammatory condition that affects an estimated 2 million women in Germany. She said sufferers can wait eight to 10 years for a diagnosis.

“If there’s a market for these medicines, and companies want that market to exist, they need to invest in basic and clinical research,” she said.

She described a 2024 survey, published in Archives of Gynecology and Obstetrics and co-authored by her, of 912 women with endometriosis in Germany, Austria and Switzerland. Among the 114 who used cannabis, 91% reported better sleep and 90% reported improvements in menstrual pain. Around nine in 10 said they reduced their use of other pain medication.

A pilot study published in PLOS One in September 2026 enrolled 30 women whose endometriosis-related pain had not responded adequately to treatment, and 27 completed the final analysis. Participants received an oral extract with equal proportions of THC and CBD alongside their existing treatment for three months. Researchers reported reductions in pain, days in pain and use of other pain medicines, plus improvements in fatigue, anxiety and several measures of wellbeing.

Mechsner stressed that the lack of a placebo group meant the study could not show how much of the improvement was due to cannabis. “What we’re really missing is a placebo-controlled study. But that requires a great deal of funding,” she said. She added that surveys would not get cannabis into clinical guidelines and that randomised controlled trials were needed.

She is planning another observational study using high-dose CBD with low THC, with an extra THC capsule on days when patients have pain.

Research designed around women

Sarshar said German healthcare figures show women use more painkillers than men, yet have higher rates of conditions including migraine and chronic back pain. “What the hell are we doing wrong in addressing women’s pain?” she asked.

She argued that research has often treated male biology as the default, overlooking differences in hormones and in how nerves and immune cells respond to pain. She also discussed how oestrogen interacts with the endocannabinoid system, and wants researchers to examine what that means for treatment, including during perimenopause and menopause.

Writing on social media after the event, she said: “What we need now is not simply more women counted in trials. We need studies deliberately designed for women.”

Relevance to the UK

In the UK, specialist doctors have been able to prescribe cannabis-based medicines since 1 November 2018, although NHS prescriptions remain rare and most patients use private clinics. CannabisHealth reported that clinics have seen growing numbers of women seeking help with pain.

Women’s health will also feature at the Cannabis Health Symposium at Conway Hall in London on 26 November, where Dr Grace Blest-Hopley of Hystelica will discuss unmet needs across menopause, endometriosis, PMDD and chronic pelvic pain.